Towards a Model-Based Dose Recommendation for Doxorubicin in Children
Swantje Völler1, Georg Hempel1, Gudrun Würthwein2
1Department of Pharmaceutical and Medical Chemistry-Clinical Pharmacy, University of Münster, Corrensstraße 48, 48149, Münster, Germany.
Clinical Pharmacokinetics
|September 20, 2016
Summary
This opinion paper discusses optimizing doxorubicin dosing for children, building on pharmacokinetic models. It aims to guide clinical trials for better pediatric cancer treatment dosing algorithms.
Area of Science:
- Pharmacology
- Pediatric Oncology
- Clinical Pharmacokinetics
Background:
- A previously published population-based model for doxorubicin pharmacokinetics in children has prompted inquiries regarding its clinical application.
- Developing effective dosing algorithms requires more than just pharmacokinetic models, necessitating clinical validation and trials.
Purpose of the Study:
- To initiate an interdisciplinary discussion on clinical and pharmacological goals for doxorubicin dose calculation in pediatric oncology.
- To summarize current knowledge on doxorubicin pharmacokinetics and pharmacodynamics in children.
- To define clinical needs for dose calculation to stimulate collaboration between pediatric oncologists and pharmacologists.
Main Methods:
- Review of existing knowledge on doxorubicin pharmacokinetics and pharmacodynamics.
- Discussion of the requirements for clinical validation and trial design for new dosing algorithms.
- Identification of potential surrogates for optimal doxorubicin dosing in pediatric patients.
Main Results:
- Highlights the need for clinical validation and trials to implement new dosing strategies.
- Emphasizes the importance of interdisciplinary collaboration for defining optimal pediatric dosing.
- Identifies the goal of establishing a rational dose calculation rule for regulatory approval and labeling.
Conclusions:
- Further research and clinical trials are necessary to validate and implement improved doxorubicin dosing strategies in pediatric oncology.
- Interdisciplinary dialogue is crucial for defining evidence-based dosing guidelines that minimize patient burden and maximize therapeutic efficacy.
- The ultimate aim is to establish a standardized, validated dosing rule for doxorubicin in children, leading to regulatory acceptance.
More Related Videos
08:34Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
21.2K
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
11.6K
Related Concept Videos
01:29Drug Dosing: Infants and Children
677
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
677
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
349
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
349
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
419
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
419
01:25Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
334
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
334
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
293
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
293
01:21Dose Size and Dosing Frequency: Determination Methods
477
Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
477